Dexmedetomidine for Non-invasive Ventilation After Chest Trauma

Summary

Crossover randomized controlled double blinded trial : * The primary endpoint is the duration of Non Invasive Ventilation (NIV) session (minutes) with dexmedetomidine (DEX) or placebo. * Secondary endpoints will be the sedation level as assessed by the Richmond Agitation Sedation Scale (RASS), the number of interventions to allow the completion of NIV session, the pain intensity level as assessed by visual analogue scale, the morphine and ketamine consumption during NIV sessions, the comparison of blood gas measurements before and after NIV sessions, the reproducibility of NIV cycles. The side effects of DEX will be notified.

Timeline

Start

2015-09

Primary completion

2017-02

Completion

2017-02

Drugs

Indications

No indication recorded.